‘Nano-Immunotherapy’ Halts Glioblastoma in Mice
August 29, 2019
By Neozene

This article originally appeared in FierceBiotech and was written by Arlene Weintraub One of the most difficult challenges in treating the brain cancer glioblastoma is that few drugs can pass through the blood-brain barrier. Scientists at Cedars-Sinai in Los Angeles have developed a system to circumvent this hurdle—one that combines a powerful immuno-oncology drug with a polymer-based delivery vehicle that can cross the blood-brain barrier. The researchers showed that this “nano-immunotherapy” treatment crossed the blood-brain barrier in mouse models of glioblastoma, and that it stopped tumor cells from multiplying. They

Read More

FDA announces overhaul of medical device approval system
November 28, 2018
By Neozene

The FDA plans to overhaul the decades-old medical device approval system that has been criticized by experts for risky implants and failure to catch problems, it announced Monday. The decision comes one day after an investigation on global medical device safety was published by the International Consortium of Investigative Journalists (ICIJ) — with over 250 journalists from more than 50 organizations helping with the investigation. The investigation found more than 1.7 million injuries and almost 83,000 deaths may have been linked to medical devices over a 10-year period in the

Read More

US FDA Clarifies Human Subject Requirements for Clinical Investigations
October 23, 2018
By Neozene

New guidance from the US Food and Drug Administration explains how its clinical investigation requirements pertaining to human subject protection policies correspond to US federal policy on human subject protections enforced by the Department of Health and Human Services (HHS). The guidance is intended to explain how sponsors whose medical device and pharmaceutical clinical investigations must meet both FDA clinical investigation regulations for human subject safety and informed consent as well as HHS’s “Common Rule” for human subject protections should address compliance issues. In general, the guidance recommends that in

Read More